QX035N is an investigational long-acting bispecific antibody that targets c-kit (a type III receptor tyrosine kinase) and another undisclosed target. C-kit is a key regulator of mast cells, and mast cells are the primary effectors in various allergic diseases. QX035N is designed to inhibit the differentiation, maturation, survival, proliferation, and degranulation of mast cells, thereby reducing and depleting mast cell populations, and is intended for the treatment of mast cell-mediated diseases. Qyuns plans to submit an Investigational New Drug (IND) application for QX035N in the second half of 2026, while also advancing its next-generation c-kit-targeting pipeline.